human tissues. 13 Therefore, it may play a functional role in placental biology and pathology.
ATF3 is a member of the large ATF/CREB (cAMP response element binding) family. It is activated by a variety of stimuli, including cytokine signaling, genotoxic agents or physiological stresses, 14, 15 and upregulated by TLR (Toll-likereceptor) activation. It is thought to function as a molecular brake to slow the TLR response (and therefore limit the innate immune response) by repressing transcription of major proinflammatory cytokines (eg, TNF-α and IL-6).
14 These effects have largely been derived from knockout (KO) mouse studies, whereby mice deficient in ATF3 are more susceptible to endotoxin shock owing to excessive cytokine production. 16, 17 However, it can also have some proinflammatory actions and, therefore, is widely considered as an immune modulator that functions in a context-dependent manner. 18 Given the reported role of ATF3 as a transcriptional repressor of the inflammatory response and its high expression in placenta, we examined whether ATF3 may be dysregulated in preeclampsia, differentially expressed with hypoxia, and play a role in regulating placental proinflammatory cytokine and antiangiogenic factor secretion.
Furthermore, Moslehi et al 19 report placental ATF3 expression in a meta-analysis containing 4 different data sets and suggest that ATF3 can indeed bind the Flt-1 promoter in mouse dendritic cells.
Materials and Methods

Tissue Collection
Women presenting to the Mercy Hospital for Women gave informed written consent for placental tissue collection. Placenta was obtained from preterm pregnancies not complicated by preeclampsia (n=26) and those complicated by severe early-onset preeclampsia (n=18). Preeclamptics were diagnosed in accordance with the American College of Obstetrician and Gynecologists guidelines 2013. 20 All samples were obtained from cases of early-onset preterm preeclampsia (<34 weeks gestation). Preterm control placentas were selected from women with preterm rupture of membranes, placental previa, or antepartum hemorrhage and who did not have any evidence of infection (histopathologic examination of the placentas), hypertensive disease, or maternal comorbidities. All patients delivered by caesarean section. Patient characteristics are outlined in Table S1 in the onlineonly Data Supplement.
Placental tissue was obtained immediately after delivery. Maternal and fetal surfaces were removed and the sample washed in sterile PBS. Samples for protein extraction were frozen within 15 minutes of delivery and stored at −80°C and samples for RNA collected in RNA later. Placenta was also fixed in 10% buffered formalin for histology. Human Ethics approval was obtained for this study from the Mercy Health Human Research Ethics Committee (R11/34).
Reverse Transcription Polymerase Chain Reaction
RNA was extracted from 50 to 100 mg frozen placental samples by homogenization or from human umbilical vein endothelial cells (HUVECs) or cytotrophoblast using an RNeasy mini-kit (Qiagen). One microgram of RNA was converted to cDNA using Applied Biosystems high-capacity cDNA reverse transcriptase (Life Technologies, Carlsbad, CA). Taqman expression assays for ATF3, TOP1 (DNA topoisomerase 1), CYC1 (cytochrome C1), YWHAZ (tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein zeta), endoglin, MMP-14 (matrix metalloproteinase 14), IL-1β, NF-κB, IL-6, TNF-α, Rab11a, Arf1, ET-1 (endothelin 1), or VCAM-1 (vascular cell adhesion molecule 1) were used. For analysis of sFlt-1 variant levels, primers targeting sFlt-1-e15a or sFlt-1-i13 were designed as previously described. 21 Reverse transcription polymerase chain reaction (RT-PCR) was performed on the CFX 384 (BioRad, Hercules, CA) using FAM-labeled Taqman universal PCR master mix (Life Technologies) with the following run conditions:  50°C for 2 minutes, 95°C for 10 minutes, 95°C for 15 seconds, and  60°C for 1 minute (40 cycles) .
Digital PCR was performed using the QuantStudio 3D Digital PCR system and master mix (Applied Biosystems) with the following conditions: 96°C for 10 minutes, 60°C for 2 minutes, 98°C for 30 seconds, and 60°C for 2 minutes (39 cycles).
Western Blot Analysis
Twenty microgram of placental lysates (preterm pregnancies not complicated by preeclampsia, n=18 and preterm pregnancies complicated by severe early-onset preeclampsia, n=15) were separated on 12% polyacrylamide gels with wet transfer to polyvinylidene fluoride membranes (Millipore, Billerica, MA). Membranes were blotted overnight with an antibody targeting ATF3 (1:200, Rabbit anti-human ATF3; Sigma) or GAPDH (1:5000; Cell Signaling Technology, Danvers, MA) and visualized using an enhanced chemiluminescence detection system (Santa Cruz Biotechnology, Santa Cruz, CA) and ChemiDoc XRS (BioRad, Hercules, CA). Relative densitometry was determined in all samples using Image Lab (BioRad).
For siRNA knockdown of ATF3, RAB11a and ARF1, 5 to 7 μg cytotrophoblast lysates was separated on 15% polyacrylamide gels. Membranes were blotted overnight with an antibody targeting either RAB11a (1:250, Rabbit anti-human Rab11a; Life Technologies), ARF1 (1:1000, Rabbit anti-human ARF1; Abcam), ATF3, or GAPDH. Membranes were visualized as indicated above.
Immunohistochemistry
ATF3 was localized by immunohistochemistry in placental tissue (preterm pregnancies not complicated by preeclampsia, n=6 and those complicated by severe early-onset preeclampsia, n=6). Paraffin sections (5 μm) were dewaxed in Xylene and rehydrated through descending grades of ethanol. Sections underwent antigen retrieval using 0.01 mol/L sodium citrate buffer (pH 6.0) for 20 minutes. After endogenous peroxidase quenching and blocking of nonspecific binding, sections were incubated overnight at 4°C with rabbit anti-ATF3 at 3 μg/mL in blocking buffer (Dako). For isotype controls, primary antibody was substituted with rabbit IgG. Staining was visualized using the SuperPicture kit (Invitrogen) followed by peroxidase substrate 3, 3′-diaminobenzidine (Dako), and lightly counterstained with Harris hematoxylin (Accustain). Staining was visualized and captured using a Leica microscope and camera.
Cytotrophoblast Isolation
Primary cytotrophoblast were isolated as previously described 22 from normal-term placentas and plated at 60% to 70% confluency in DMEM containing 10% fetal calf serum for siRNA experiments or 80% to 90% confluency for hypoxia experiments. Cytotrophoblasts were maintained in a humidified incubator at 8% O 2 (normoxia) or 1% O 2 (hypoxia) and 5% CO 2 .
Placental Explants
Placental explants were collected from term placentas. Maternal and fetal surfaces were removed before small (1 mm 3 ) explants of villous tissue were dissected. Three villous explants were used per well in triplicate wells. Placental explants were maintained in a humidified incubator at 8% O 2 (normoxia) or 1% O 2 (hypoxia) and 5% CO 2 .
Isolation of Primary HUVECs
HUVECs were isolated as previously described. [23] [24] [25] Cells were cultured in M199 media (Life Technologies) containing 10% fetal calf serum, 1% anti-anti and 1% endothelial cell growth factor (Sigma), and 1% heparin and used between passages 2 to 4. Primary HUVECs were maintained in a humidified incubator with room concentration O 2 at 5% CO 2 . November 2017
Transcription Factor Binding Site Analysis
Transcription factor binding sites were identified using JASPAR database (http://jaspar.genereg.net/). DNA sequences were obtained from the University of California, Santa Cruz genome browser (http://genome.ucsc.edu) and transcription factor binding sites identified using JASPAR database (http:// jaspar.genereg.net/) for ATF3, NF-κB, or STAT-3 within a region spanning 1 kb of the promoter of Flt-1 and endoglin.
siRNA Knockdown of ATF3, Rab11a, Arf1, and HIF-1α siRNA targeting ATF3 was administered to primary cytotrophoblast or primary HUVECs at 10 nmol/L or a matching concentration of scrambled (negative) siRNA (Qiagen, Limburg, The Netherlands). For Rab11a and Arf1, 40 or 10 nmol/L of siRNA was administered to primary cytotrophoblast, respectively. For HIF-1α (hypoxia-inducible factor 1α), 20 nmol/L of siRNA was administered. Primary cytotrophoblast were cultured for 96 hours, with media changed at 24 and 72 hours post-transfection. Primary HUVECs were cultured for 72 hours with media changed at 24 and 48 hours post-transfection.
Ten μmol/L of CpG or CpG control (Invivogen, SanDiego, CA) was added at 48 hours post-transfection, and the experiment continued for 96 hours post-transfection.
Culture media was collected for analysis by ELISA and RNA collected for analysis by RT-PCR. Given the low secretion of sEng from primary cytotrophoblast, 26 culture media was concentrated 10× using concentrating spin columns (Millipore) to provide endoglin reads well within the standard curve. Knockdown efficiency of ATF3, Rab11a, and Arf siRNA in both primary HUVEC and cytotrophoblast was confirmed by quantitative RT-PCR and Western Blot.
ELISA Analysis
sFlt-1, sEng, and IL-6 were measured in conditioned cell media using the Human VEGF/R1 Duoset ELISA kit, Human Endoglin CD/105 Duoset ELISA kit, and the Human IL-6 Duoset ELISA kit (R&D Systems by Bioscience, Waterloo, Australia) according to the manufacturer's instructions. Concentration of sFlt-1 in mouse pregnancy serum was determined using the mouse VEGF/R1 Duoset ELISA kit (R&D Systems).
Brefeldin A Treatment of Primary Cytotrophoblast
Primary cytotrophoblast were treated with Brefeldin A (Sigma) at 0, 1.25, 2.5, 5, and 10 ng/mL for 24 hours. MTS indicated no significant effect on cell viability at these doses. Media was collected and subjected to sFlt-1 ELISA.
NF-κB Luciferase Assay
Primary cytotrophoblast were transfected using an NF-κB Cignal Reporter (Qiagen) in the presence of either ATF3 siRNA or scrambled siRNA. At 72 hours post-transfection, the luciferase activity was determined using the Luciferase reporter assay kit (RayBiotech, Norcross, GA). Luciferase activity was measured using a FLUOstar OMEGA plate reader (BMG Labtech, Ortenberg, Germany).
Endothelial Dysfunction
Endothelial dysfunction was induced by treatment of primary HUVECs for 24 hours with cytotrophoblast-conditioned media collected from cytotrophoblast that had been exposed to either ATF3 siRNA or scrambled siRNA for 96 hours. Media was applied to HUVECs for 24 hours before cell lysates were subjected to RNA extraction and RT-PCR for ET-1 and VCAM-1 as described above.
ATF3 KO Mice: Breeding and Monitoring of Pregnancy Outcome
ATF3 KO and wild-type littermates were obtained via donation from Professor Tsonwin Hai, Ohio State University. 18 The University of Melbourne Animal Ethics Committee approved all animal experiments. At embryonic day 8.5 (E8.5), mice were randomly assigned to receive either 5 μg CpG (Invivogen) or 5 μg CpG control (Invivogen) intraperitoneally daily until E18.5. n=5 mice were included in each group.
At E18.5, urine was collected for determination of urinary albumin/creatinine ratio, and mice were killed via cervical dislocation. Cardiac puncture was performed to obtain maternal blood for measurement of sFlt-1. Litter size, pup weight, and placental weight were recorded.
ATF3 KO Mice: Blood Pressure Measurements
Blood pressure was monitored in ATF3 KO and littermate controls at E14.5, E16.5, and E18.5 using the CODA tail-cuff method. Ten acclimation-recording cycles of 20 seconds each were initially made, followed by 20 measurement-recording cycles of 20 seconds. Total length of time for recording was 10 minutes (30 cycles @20 seconds=600 seconds=10 minutes).
Urinary Albumin/Creatinine Measurement
Mouse urinary albumin/creatinine levels were measured using commercially available Mouse albumin ELISA and Mouse creatinine ELISA according to the manufacturer's instructions (Crystal Chem, IL).
Statistical Analysis
Triplicate technical replicates were performed for each experiment, with a minimum of 3 independent biological replicates performed for each in vitro study. Data were tested for normal distribution and statistically analyzed as appropriate. When ≥3 groups were compared, a 1-way ANOVA (for parametric data) or Kruskal-Wallis test (for nonparametric data) was used. Post hoc analysis was performed using either the Tukey (parametric) or Dunn test (nonparametric). When 2 groups were analyzed, either an unpaired t test (parametric) or a Mann-Whitney test (nonparametric) was used. All data are expressed as mean±SEM. P values <0.05 were considered significant. Statistical analysis was performed using GraphPad Prism 7 software (GraphPad Software, La Jolla, CA).
Results
ATF3 Expression Is Reduced in Preeclamptic Placentas
We initially characterized ATF3 in preterm preeclamptic placentas ( Figure 1 ). ATF3 mRNA ( Figure 1A ), absolute copy number ( Figure 1B , measured by digital PCR), and protein expression ( Figure 1C and 1D) were significantly (P<0.05) reduced in preterm preeclamptic placenta compared with gestationally matched normotensive controls. We also found that ATF3 mRNA ( Figure 1A ) and protein ( Figure 1C ) were significantly elevated (relative to the preterm group) in control samples obtained at >34 weeks gestation. ATF3 was localized to the nuclei of the syncytiotrophoblast ( Figure 1E ).
ATF3 Expression Is Reduced With Hypoxia
Preeclampsia is associated with poor placental perfusion and placental hypoxia; thus, we assessed whether hypoxia altered ATF3 expression in primary placental cells and tissue. Hypoxia significantly reduced ATF3 mRNA expression in primary cytotrophoblast by 53% (Figure 2A ) and placental explants by 42% ( Figure 2B ). We next silenced HIF-1α under normoxic and hypoxic conditions in primary cytotrophoblast and assessed the effect on ATF3 mRNA expression. We confirmed robust knockdown of HIF-1α under both hypoxia (1% O 2 ) and normoxia (8% O 2 ; Figure 2C ) in primary cytotrophoblast. As expected, hypoxia significantly reduced ATF3 mRNA expression, but silencing HIF-1α did not alter this effect ( Figure 2D ). Thus, our data suggest that although ATF3 is regulated by hypoxia, this effect is not mediated via HIF-1α.
Silencing ATF3 Increases Placental Proinflammatory Cytokine Expression
We next silenced ATF3 in primary cytotrophoblast and examined the effects on proinflammatory cytokine expression.
We confirmed we silenced ATF3 at both the mRNA and protein level ( Figure S1A and S1B). Silencing ATF3 significantly increased IL-6, TNF-α, and NF-κB mRNA expression ( Figure 3A, 3B, and 3D) . Secretion of proinflammatory cytokines from primary cytotrophoblast was modest-we only detected IL-6, which showed a significant increase when ATF3 was silenced. Silencing ATF3 also significantly increased NF-κB luciferase activity in placenta ( Figure 3F) .
We conclude that in a setting of reduced ATF3 expression, placental inflammation is increased. This infers that placental ATF3 transcriptionally represses proinflammatory cytokines in placenta.
Silencing ATF3 Increases sFlt-1 and sEng Release From Primary Cytotrophoblast
A common upstream mechanism that molecularly regulates the increased secretion of both sFlt-1 and sEng 3, 11, 27 has yet to be described. We performed in silico analyses of predicted ATF3 binding sites on various promoters to determine whether ATF3 might transcriptionally regulate sFlt-1 and endoglin. We Silencing ATF3 in primary cytotrophoblast significantly increased sFlt-1 secretion ( Figure 4A ). It has previously been shown that fetal/placenta DNA released into the maternal circulation in preeclamptic pregnancies stimulates TLR-9 signaling. 28 Under normal circumstances, ATF3 is activated by TLR stimulation. Therefore, we tested the effect of activating TLR-9 signaling in a setting of reduced ATF3 expression (to mimic the reduction we observe in preeclamptic placenta). To do this, we silenced ATF3 and administered TLR-9 ligand CpG. We found that stimulating TLR-9 in a setting of reduced ATF3 further enhanced sFlt-1 secretion ( Figure 4A ). Silencing ATF3 induced a trend toward increased Flt-1 mRNA, which was significant after TLR-9 stimulation ( Figure 4B ). No significant differences in the mRNA expression of the sFlt-1 splice variants, sFlt-1-e15a or sFlt-1-i13, were identified ( Figure 4C and 4D ). Besides placenta, endothelial cells are Figure 2 . ATF3 (activating transcription factor 3) is reduced under hypoxic conditions. ATF3 mRNA expression was significantly reduced when (A) primary cytotrophoblast or (B) placental explants were exposed to 1% O 2 (hypoxia). To assess the effect of HIF-1α (hypoxiainducible factor 1α) on ATF3, siRNA targeting HIF-1α or scrambled siRNA (siNeg) was administered under both hypoxic and normoxic conditions to primary cytotrophoblast. C, Knockdown of HIF-1α mRNA was confirmed under both normoxic and hypoxic conditions. D, When HIF-1α was silenced under normoxia or hypoxia, there was no change in ATF3 expression compared with siNeg. Data expressed as mean±SEM. ***P<0.001, n=3 to 5 separate patient samples used with each sample run in triplicate. the second main source of circulating sFlt-1. Silencing ATF3 in primary HUVECs significantly increased sFlt-1 secretion ( Figure S1D ) and mRNA expression of the sFlt-1 endothelial variant, sFlt-1-i13 ( Figure S1E ) but not the placental variant sFlt-1-e15a ( Figure S1F ). Together, these data suggest that ATF3 negatively regulates Flt-1 and sFlt-1 in placental and endothelial cells.
Silencing ATF3 also significantly increased sEng secretion ( Figure 4E ), possibly via increased endoglin transcription ( Figure 4F) . We have previously shown that MMP-14 is the molecular scissors that cleaves endoglin at the cell surface to release sEng. 29 Assessment of MMP-14 mRNA expression, however, indicated no significant effect on MMP-14 after ATF3 silencing ( Figure S1G ) or on its natural inhibitor TIMP3 (tissue inhibitor of metalloproteinase 3) ( Figure S1H ). We also confirmed that ATF3 knockdown significantly increased sEng release from primary HUVECs (Figure S1I ), as well as significantly increased both endoglin and MMP-14 mRNA expression ( Figure S1J and S1K) in those cells. TIMP3 expression was also increased by ATF3 silencing ( Figure S1L) .
Together, our data suggest that ATF3 is a molecule that negatively regulates both sFlt-1 and sEng release from placenta and endothelial cells.
Silencing ATF3 Increases Cargo Proteins Involved in Shuttling sFlt-1 Out of Cells
We next considered whether there might be an additional mechanism by which sFlt-1 secretion is increased when ATF3 expression is reduced. We assessed whether reduced placental ATF3 affected transport proteins, ARF1 and RAB11a, previously implicated in sFlt-1 secretion from primary HUVEC and placental cell lines. 30 Given ARF1 functions by transporting proteins from the endoplasmic reticulum to the Golgi, we initially confirmed that inhibiting the endoplasmic reticulum to Golgi transport impaired sFlt-1 release from primary cytotrophoblast by administering Brefeldin A, an inhibitor of endoplasmic reticulum to Golgi transport. As expected, Brefeldin A induced a dose-dependent reduction in sFlt-1 secretion ( Figure S2A ). We also confirmed silencing RAB11a and ARF1 significantly reduced sFlt-1 secretion from primary cytotrophoblast (Figure 5A and 5B; Figure S2B through S2I). When we silenced ATF3 in primary cytotrophoblast, we observed a significant increase in the mRNA expression of both ARF1 and RAB11a ( Figure 5C and 5E) and a trend toward increased protein expression ( Figure 5D and 5F ). This demonstrates that silencing ATF3 may also upregulate key sFlt-1 export molecules in placenta.
Reduced Placental ATF3 Expression Upregulates Markers of Endothelial Dysfunction
Preeclampsia is characterized by systemic endothelial dysfunction. We silenced ATF3 in primary cytotrophoblast, collected the conditioned media (which contains secreted cytotrophoblast factors), and administered this media to primary endothelial cells (HUVECs; Figure 6A and 6B). We have previously reported that exposure of primary HUVECs to cytotrophoblast-conditioned media induces markers of endothelial dysfunction, VCAM-1, and ET-1. 24 Here we demonstrated that exposure of primary HUVECs to cytotrophoblast-conditioned media from cells where ATF3 was silenced produced significantly elevated VCAM-1 expression ( Figure 6A ) compared with cells exposed to control media. In Figure 4 . ATF3 (activating transcription factor 3) knockdown stimulates sFlt-1 (soluble fms-like tyrosine kinase 1) and sEng (soluble endoglin) release from primary cytotrophoblast. siRNA knockdown of ATF3 produced (A) significantly increased sFlt-1 secretion, which was further increased by TLR-9 (Toll-like-receptor 9) stimulation. It also produced (B) increased Flt-1 mRNA transcription, which was significant after TLR-9 stimulation but had no effect on (C) sFlt-1-e15a or (D) sFlt-1-i13 mRNA expression. ATF3 siRNA also produced (E) significantly increased sEng release, attributable to (F) significantly increased endoglin expression. Data expressed as mean±SEM. *P<0.05, **P<0.01, ***P<0.001, n=3 to 5 separate patient samples used with each sample run in triplicate. Figure 5 . sFlt-1 (soluble fms-like tyrosine kinase 1) transport protein expression is elevated when ATF3 (activating transcription factor 3) is silenced. We next assessed the importance of the transport proteins Rab11a and Arf1 to sFlt-1 release. siRNA knockdown of both (A) Rab11a and (B) Arf1 produces significantly reduced sFlt-1 secretion. Interestingly, knockdown of ATF3 produced significantly increased (C) Rab11a and (E) Arf mRNA expression. D and F, Analysis of protein expression after knockdown in n=3 trophoblast isolations demonstrated a trend toward increased protein expression, suggesting increased secretion of sFlt-1 after knockdown of ATF3 may also be partly attributable to changes in transport protein expression. Data expressed as mean±SEM. **P<0.01, ***P<0.001, ****P<0.0001, n=3 to 5 separate patient samples used with each sample run in triplicate.
contrast, no significant alteration in ET-1 (a potent vasoconstrictor secreted into the circulation from the endothelium and elevated in preeclampsia) was observed ( Figure 6B ).
Pregnancy Phenotype of ATF3 KO Mice
Finally, we assessed the pregnancy phenotype of ATF3 KO mice. Four groups of mice were compared: wild-type control mice, wild-type mice given CpG, ATF3 KO control mice, and ATF3 KO mice given CpG. sFlt-1 secretion ( Figure S3A ) was not altered in any of the groups, and no significant differences in mean arterial blood pressure ( Figure S3B ) or urinary albumin/creatinine ratio between groups ( Figure S3C ) was identified.
No significant alterations in litter size were observed among groups ( Figure S3D ). Compared with wild-type CpG controls, wild-type mice treated with CpG produced significantly smaller placentas ( Figure S3E ). Smaller placentas were also identified for both the control CpG and CpG administered KO mice ( Figure S3E ). No significant differences in pup weight ( Figure S3F ) or pup length ( Figure S3G ) were identified in wild-type mice, whereas KO mice administered CpG produced pups that were significantly increased in weight and length. However, this effect was not significantly different to the KO mice administered control CpG. Thus, we conclude that the ATF3 KO mice did not display a preeclamptic phenotype. This is not entirely surprising given preeclampsia is a disease unique to women and some higherorder primates.
Discussion
We have previously identified 137 genes by in silico analyses that are most abundantly expressed in placenta relative to all other human tissues. There has been limited study around the role of most of these genes in pregnancy complications. We speculate that many may make a major contribution to placental diseases such as preeclampsia. [31] [32] [33] [34] ATF3 is one such gene, and here we have characterized its expression in preeclampsia and assessed its potential functional contribution to the disease.
Our study demonstrates that placental ATF3 expression is significantly reduced in severe early-onset preeclamptic placentas. We have found that this transcription factor is regulated by hypoxia and seems to be an upstream negative regulator of placental inflammatory cytokines and antiangiogenic factors sFlt-1 and sEng. Thus, we propose that chronic placental hypoxia (that occurs in preeclampsia as a result of compromised maternal blood flow to the placenta because it failed to properly implant during the first trimester) downregulates ATF3 (in a HIF-1α-independent manner). Reduced ATF3 allows the expression of proinflammatory cytokines and sFlt-1 and sEng secretion to go unchecked, resulting in their upregulation. These factors are then released into the maternal circulation to cause the maternal clinical manifestations of the disease. Thus, our data suggest that placental ATF3 is a novel transcription factor reduced and potentially contributing to the pathogenesis of preeclampsia.
Although highly expressed in placenta, there seems to have been limited previous investigation into ATF3 expression in preeclampsia. We note 1 study by Moslehi et al 19 where they performed a bioinformatics analysis of microarray data and reported that ATF3 is in fact increased in preeclampsia, which is contrary to our findings. However, we note that Moslehi et al 19 combined data from 4 reports, which were a heterogeneous mix of preterm and term placenta samples, and significantly, there was no PCR or protein validation of their in silico analysis. Of note, out of the 50 preeclamptic samples they analyzed, at least 16 were compared with normal-term placentas failing to account for gestational age. 35 In contrast, we examined a large bank of placentas collected contemporaneously using a uniform protocol at a single site. Importantly, in selecting our samples from our biobank, we carefully matched for gestational age. We found a consistent decrease in ATF3 at both the mRNA (using 2 PCR approaches, real time and digital PCR) and protein level. Given ATF3 is a transcription factor, we think confirmation of protein changes is essential, and importantly, it robustly verifies our RNA data. Thus, our data provides strong evidence to indicate that placental ATF3 expression is significantly reduced in preterm preeclampsia.
Prolonged placental hypoxia is thought to be an important aspect of the pathogenesis of preeclampsia. [36] [37] [38] Primary placental cells exposed to hypoxia readily secrete high levels of sFlt-1 2 . Our data demonstrates that ATF3 is significantly reduced in both primary placental cytotrophoblast and primary placental explants after exposure to hypoxia. This finding is concordant with a previous report of ATF3 expression in peripheral blood mononuclear cells, where it was demonstrated that ATF3 was one of many transcriptional regulators found to be downregulated in peripheral blood mononuclear cells from pregnant women exposed to chronic hypoxia. 39 ATF3 expression in low oxygen has also been previously assessed in solid tumors. 40 In that study, Ameri et al 40 showed that ATF3 was significantly increased under anoxia. Interestingly, its upregulation with anoxia occurred independent of HIF-1α. Thus, both this study 40 and our study demonstrate that changes in ATF3 mRNA expression at low oxygen occur independently of HIF-1α. To our knowledge, the study by Moslehi et al 19 is the only other report to have assessed ATF3 expression in trophoblast exposed to hypoxia. In this study, Moslehi et al 19 assessed 285 genes they had found to be upregulated in preeclamptic placentas via a meta-analysis (including ATF3) and report that 65 of these genes were also upregulated in Swan 71 cells (a trophoblast cell line) exposed to chemical hypoxia. However, ATF3 was not one of the genes reported to be differentially regulated in hypoxia. This is in contrast to our work where we found that hypoxia significantly downregulated ATF3 expression in both primary cytotrophoblast and placental explants. This differential finding may be reflective of the differences between primary cells and tissues compared with the Swan 71 cell line. In addition, our experimental data were derived from cells exposed to 1% (hypoxia) versus 8% (normoxia) oxygen tensions, which is likely to produce different effects to cells exposed to chemical hypoxia or a vehicle control.
Our finding that silencing ATF3 increases transcription and secretion of proinflammatory cytokines suggests that ATF3 may indeed function as a molecular brake 14 in placentas.
Intriguingly, although Moslehi et al 19 previously demonstrated that ATF3 binds to the Flt-1 promoter in mouse dendritic cells and our in silico analysis demonstrated an ATF3 binding site 131 bp upstream of the Flt-1 start site, we were unable to directly show an effect of silencing ATF3 on placental Flt-1 transcription. However, we did demonstrate that ATF3 seems to be a negative regulator of sFlt-1 secretion. This is an intriguing find given the lack of understanding surrounding the regulation of sFlt-1 secretion in preeclampsia to date. Our further analysis suggested that the effect of silencing ATF3 on sFlt-1 secretion may occur via dysregulation of sFlt-1 transport proteins RAB11a and ARF1. We showed that silencing placental ATF3 resulted in increased mRNA and protein expression of RAB11a, one of the proteins responsible for shuttling sFlt-1 from the Golgi complex out of the cell. Thus, we propose that the reduced ATF3 we observe in preeclamptic placenta may indirectly upregulate sFlt-1 secretion via upregulation of the sFlt-1 transport proteins.
Interestingly, we did not find a preeclampsia phenotype in the ATF3 KO mice. The reason for this disparity between the mouse data and our human data is likely to be a reflection of species specificity for ATF3 and placental function. It is important to note that preeclampsia is a disease that occurs only in humans and higher-order primates. It does not occur naturally in wild-type mice. The human specificity of preeclampsia is thought to be a result of the highly invasive nature of implantation in women relative to other hemochorial species. As such, the human placenta is very different from all other animals. Second, preeclampsia is strongly associated with aberrantly elevated levels of placental sFlt, which is likely to be a major driver of the pathogenesis of sFlt-1. In humans, the major sFlt-1 isoform is sFlt-1-e15a, 41 ,42 a variant which is human (and largely placental) specific and does not exist in mice. Thus, we think it is highly plausible that the upstream mechanism regulating sFlt-1 production may be species specific and unique to humans.
Finally, it is important to note that although in humans the placenta has the highest expression of ATF3 compared with all other human tissues, this is not the case in mice, where in fact higher ATF3 expression is found within the immune cell population. 43 It is possible that this abundant ATF3 expression present in human placenta (but not mice) might have a noncanonical regulatory role (such as sFlt-1 regulation) beyond immune system regulation, and that it is species specific.
Perspectives
The findings from this study provide new and novel data to indicate that reduced ATF3 expression may be a central link in the pathogenesis of preeclampsia. We now have evidence to show that ATF3 is significantly reduced in preeclamptic placenta. Our data suggest that ATF3 expression may be reduced by hypoxia, which in turn negatively regulates sFlt-1 and sEng in placental cells, providing a putative link between placental hypoxia and sFlt-1 and sEng secretion. Moreover, reduced ATF3 also results in increased placental inflammation, which may be worsened by stimulation of TLR-9. Thus, we have found a molecule that may represent a central axis to the pathophysiology of this disease: hypoxia, inflammation, and the elevated secretion of sFlt-1 and sEng. As such, its dysregulation may have a major role in the pathophysiology of preeclampsia.
